Short Interest in Genetic Technologies Limited (NASDAQ:GENE) Decreases By 44.5%

Genetic Technologies Limited (NASDAQ:GENE) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 8,100 shares, a decline of 44.5% from the August 15th total of 14,600 shares. Based on an average trading volume of 47,100 shares, the days-to-cover ratio is currently 0.2 days.

Genetic Technologies Stock Down 2.5 %

NASDAQ GENE traded down $0.02 on Friday, reaching $0.80. 20,057 shares of the company were exchanged, compared to its average volume of 45,187. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.55 and a current ratio of 1.67. The business’s fifty day moving average price is $0.87 and its 200 day moving average price is $1.80. Genetic Technologies has a fifty-two week low of $0.69 and a fifty-two week high of $4.65.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genetic Technologies stock. Armistice Capital LLC acquired a new position in Genetic Technologies Limited (NASDAQ:GENE) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 140,000 shares of the biotechnology company’s stock, valued at approximately $210,000. Armistice Capital LLC owned 3.18% of Genetic Technologies as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 0.63% of the company’s stock.

Genetic Technologies Company Profile

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments.